A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism.

SR-1664 is a novel potent, non-agonist PPARγ ligand that blocks the Cdk5-mediated phosphorylation in vitro (IC50=80 nM) and in vivo, without the classical agonism.

Bezafibrate(BM15075) is the first clinically tested dual and pan-PPAR co-agonism.

BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.

CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.

Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.

Fenofibrate is PPARα agonist with EC50 of 18 μM and 30 μM for mouse and human PPARα, respectively.

Fonadelpar (NPS-005,SJP-0035) is a potent, selective peroxisome proliferator activated receptor δ (PPARδ) agonist for the treatment of corneal disorders..

GSK-0660 is a selective PPARδ antagonist (IC50 values are 0.155, > 10 and ≥ 10 μM at PPARδ, PPARα and PPARγ respectively).

GSK3787 is as a potent and selective antagonist of PPARδ with pIC50 of 6.6.

GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.

GW-0742 is a potent and highly selective PPARδ agonist.

GW1929 is a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist with IC50 of 6.2 nM and 13 nM for human and mouse, respectively.

GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.

GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.

L-165041 is a potent PPARδ agonist (Ki = 6 nM).

Lanifibranor, also known as IVA-337, is a peroxisome proliferator-activated receptors (PPAR) agonist.

MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.

Palmitoylethanolamide(PEA) is an endogenous fatty acid amide and selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM.

Pemafibrate is an orally bioavailable and selective agonist of peroxisome proliferator-activated receptor α (PPARα; EC50 = 1 nM for transcriptional activity), a transcription factor that is essential for regulation of lipid homeostasis.

Pioglitazone Hydrochloride is the hydrochloride salt preparation of Pioglitazone, a specific ligand of PPAR-γ (peroxisome proliferator-activated receptor-γ). Pioglitazone is a thiazolidinedione compound described to produce antiinflammatory and antiarteri

RB394 is an orally bioavailable and dual modulator of soluble epoxide hydrolase (sEH) and PPARγ.